|
|
- 2017
TREM-1和COX-2在直肠癌组织中的表达及其与预后的关系
|
Abstract:
摘要：目的 检测TREM-1、COX-2在直肠癌组织及癌旁组织中的表达差异，探讨二者与临床病理特征的关系，及其对患者生存的影响。方法 应用免疫组织化学法，对68例直肠癌组织和50例癌旁组织的TREM-1和COX-2的表达进行检测。并对患者定期随访，分析两因子与预后的关系。结果 直肠癌组织中TREM-1、COX-2的阳性表达率高于癌旁组织(P<0.05)。TREM-1的表达与淋巴结转移相关，COX-2与病理分期、淋巴结转移相关(P<0.05),两因子与年龄、性别、组织分化程度及肿瘤大小无关。两者之间的表达呈正相关(r=0.550，P<0.001)。TREM-1、COX-2阳性表达组总生存期(OS)均较阴性组缩短(P<0.05)。COX多元回归分析显示TREM-1的表达、病理分期、淋巴结有无转移、肿物大小对预后有影响。结论 TREM-1、COX-2在直肠癌组织中表达增高，提示两者可能促进直肠癌的发展和淋巴结转移，且二者的表达与患者不良预后相关。
ABSTRACT: Objective To detect the differences of triggering receptor expressed on myeloid cells-1 (TREM-1) and cyclo-oxygenase-2 (COX-2) expressions in rectal cancer tissues and carcinoma adjacent tissues so as to explore the relationship between the two factors and clinical pathological characteristics and their effects on the patients’ survival. Methods The expressions of TREM-1 and COX-2 were analyzed in 68 cases of rectal cancer tissues and 58 cases of carcinoma adjacent tissues with the method of immunohistochemical staining. We made a regular follow-up of the patients, analyzed the relationship between the two factors and prognosis of rectal cancer. Results The positive expression rates of TREM-1 and COX-2 in rectal cancer tissues were higher than those in carcinoma adjacent tissues (P<0.05). The expression of TREM-1 was related to lymph node metastasis, while COX-2 was related to pathological stage and lymph node metastasis (P<0.05). However, the two factors were not related to age, sex, histological differentiation or tumor size. The expressions of the two factors were positively correlated (r=0.550, P<0.001). The overall survival (OS) of TREM-1 and COX-2 positive expression groups was shorter than that of the negative groups (P<0.05). Cox multiple regression analysis showed that the expression of TREM-1, pathological stage, lymph node metastasis and tumor size affected the prognosis. Conclusion The expressions of COX-2 and TREM-1 in rectal cancer increase, suggesting that the two factors may promote the development and lymph node metastasis of rectal cancer, and the expressions of the two factors are related to the patients’ poor prognosis
| [1] | GRIVENNIKOV SI. Inflammation and colorectal cancer: Colitis-associated neoplasia[J]. Semin Immunopathol, 2012, 35(2):229-244. |
| [2] | SCHENK M, BOUCHON A, SEIBOLD F, et al. TREM-1-expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases[J]. J Clin Invest, 2007, 117(10):3097-3106. |
| [3] | ECHIZEN K, HIROSE O, MAEDA Y, et al. Inflammation in gastric cancer: Interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways[J]. Cancer Sci, 2016, 107(4):391-397. |
| [4] | PRABHU KCL, LAN V, CHAN SK, et al. Predictive utility of cyclo-oxygenase-2 expression by colon and rectal cancer[J]. Am J Surg, 2014, 207(5):712-716. |
| [5] | LIN PC, LIN YJ, LEE CT, et al. Cyclooxygenase2 expression in the tumor environment is associated with poor prognosis in colorectal cancer patients[J]. Oncol Lett, 2013, 6(3):733-739. |
| [6] | 钟华, 刘迪群. 结直肠癌组织中Ki-67和COX-2的表达及其临床意义[J]. 吉林大学学报(医学版), 2016, 42(6):1168-1172. |
| [7] | YOSHINAGA M, TAKI K, SOMADA S, et al. The expression of both peroxisome proliferator-activated receptor delta and cyclooxygenase-2 in tissues is associated with poor prognosis in colorectal cancer patients[J]. Digest Dis Sci, 2011, 56(4):1194-1200. |
| [8] | BOSCO M C, RAGGI F, VARESIO L. Therapeutic potential of targeting TREM-1 in inflammatory diseases and cancer[J]. Curr Pharm Design, 2016, 22:1-25. |
| [9] | SCHENK M, BOUCHON A, BIRRER S, et al. Macrophages expressing triggering receptor expressed on myeloid cells-1 are underrepresented in the human intestine[J]. J Immunol, 2005, 174(1):517-524. |
| [10] | BOSTANCI N，THURNHEER T，BELIBASAKIS GN. Involvement of the TREM-1/DAP12 pathway in the innate immune responses to porphyromonas gingivalis[J]. Mol Immunol, 2011, 49(1/2):387-394. |
| [11] | ROTHWELL PM, WILSON M, ELWIN CE, et al. Long-term effect of aspirin oncolorectal cancer incidence and mortality: 20-year follow-up of five randomised trials[J]. Lancet, 2010, 376(9754):1741-1750. |
| [12] | BROWN CJ, GALLINGER S, CHURCH J. Long-term effects of aspirin on colorectal cancer[J]. J Am Coll Surgeons, 2012, 214(6):1023-1026. |
| [13] | SHISHODIA S, KOUL D, AGGARWAL BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-κB activation through inhibition of activation of IκBα kinase and Akt in human non-small cell lung carcinoma: Correlation with suppression of COX-2 synthesis[J]. J Immunol, 2004, 173(3):2011-2022. |
| [14] | TORIOLA AT, CHENG TYD, NEUHOUSER ML, et al. Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers[J]. Int J Cancer, 2013, 132(11):2648-2658. |
| [15] | DUAN M, WANG ZC, WANG XY, et al. TREM-1, an inflammatory modulator, is expressed in hepatocellular carcinoma cells and significantly promotes tumor progression.[J]. Ann Surg Oncol, 2015, 22(9):3121-3129. |
| [16] | EMIR S, AYDIN M, CAN G, et al. Comparison of colorectal neoplastic polyps and adenocarcinoma with regard to NLR and PLR[J]. Eur Rev Med Pharmacol Sci, 2015,19(19):3613-3618. |
| [17] | ZHOU JG, CHAI F, LU G, et al. TREM-1 inhibition attenuates inflammation and tumor within the colon[J]. Int Immunopharmaco, 2013,17(2): 155-161. |
| [18] | LIAO R, SUN TW, YI Y, et al. Expression of TREM-1 in hepatic stellate cells and prognostic value in hepatitis B-related hepatocellular carcinoma[J]. Cancer Sci, 2012, 103(6):984-992. |
| [19] | HO CC, LIAO WY, WANG CY, et al. TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer[J]. Am J Resp Criti Care, 2008, 177(7):763-770. |
| [20] | YUAN Z, MEHTA HJ, MOHAMMED K, et al. TREM-1 is induced in tumor associated macrophages by cyclo-oxygenase pathway in human non-small cell lung cancer[J]. PLoS One, 2014, 9(5):e94241-e94241. |
| [21] | PENG ZH, WAN DS, LI LR, et al. Expression of COX-2, MMP-2 and VEGF in stage II and III colorectal cancer and the clinical significance[J]. Hepato-gastroenterol, 2011, 58(106):369-376. |
| [22] | BENDARDAF R, BUHMEIDA AM, LAATO M, et al. VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival[J]. Anticancer Res, 2008, 28(6B):3865-3870. |
| [23] | SI R, WU SH, HE S, et al. Clinical significance of expression of p85a, nm23 and MMP-2 in primary colorectal cancer and lymph node metastasis[J]. WCJD, 2014, 22(36):5623-5630. |
| [24] | O’Neill L A J. How Toll-like receptors signal: What we know and what we don’t know[J]. Curr Opin Immunol, 2006, 18(1):3-9. |
